MedPath

Cefotaxime

CEFOTAXIME FOR INJECTION, USP

Approved
Approval ID

ed23b6bc-32c7-4c50-a53d-313ae78e5623

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

May 25, 2021

Manufacturers
FDA

Hikma Pharmaceuticals USA Inc.

DUNS: 001230762

Products 3

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Cefotaxime

PRODUCT DETAILS

NDC Product Code0143-9930
Application NumberANDA065072
Marketing CategoryC73584
Route of AdministrationINTRAMUSCULAR, INTRAVENOUS
Effective DateMay 25, 2021
Generic NameCefotaxime

INGREDIENTS (1)

CEFOTAXIME SODIUMActive
Quantity: 500 mg in 1 1
Code: 258J72S7TZ
Classification: ACTIM

Cefotaxime

PRODUCT DETAILS

NDC Product Code0143-9931
Application NumberANDA065072
Marketing CategoryC73584
Route of AdministrationINTRAMUSCULAR, INTRAVENOUS
Effective DateMay 25, 2021
Generic NameCefotaxime

INGREDIENTS (1)

CEFOTAXIME SODIUMActive
Quantity: 1 g in 1 1
Code: 258J72S7TZ
Classification: ACTIM

Cefotaxime

PRODUCT DETAILS

NDC Product Code0143-9933
Application NumberANDA065072
Marketing CategoryC73584
Route of AdministrationINTRAMUSCULAR, INTRAVENOUS
Effective DateMay 25, 2021
Generic NameCefotaxime

INGREDIENTS (1)

CEFOTAXIME SODIUMActive
Quantity: 2 g in 1 1
Code: 258J72S7TZ
Classification: ACTIM

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Cefotaxime - FDA Drug Approval Details